Search | OpenScholar

Search results

1502 results found

Caffeine, creatine, GRIN2A and Parkinson's disease progression. J Neurol Sci 2017;375:355-359.

Publication: Journal Article

Simon, DK, C Wu, BC Tilley, K Lohmann, C Klein, H Payami, AM Wills, et al. 2017. “Caffeine, Creatine, GRIN2A and Parkinson’s Disease Progression. J Neurol Sci 2017;375:355-359.”. J Neurol Sci .

Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Psychiatry 2017;4:595-604.

Publication: Journal Article

Anderson, KE, D Stamler, MD Davis, SA Factor, RA Hauser, J Isojarvi, LF Jarskog, et al. 2017. “Deutetrabenazine for Treatment of Involuntary Movements in Patients With Tardive Dyskinesia (AIM-TD): A Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial. Lancet Psychiatry 2017;4:595-604.”. Lancet Psychiatry.

Seeberger LC, Hauser RA.Valbenazine for the treatment of tardive dyskinesia. Expert Opin Pharmacother 2017;18:1279-1287.

Publication: Journal Article

Seeberger, LC, and RA Hauser. 2017. “Seeberger LC, Hauser RA.Valbenazine for the Treatment of Tardive Dyskinesia. Expert Opin Pharmacother 2017;18:1279-1287.”. Expert Opin Pharmacother.

Droxidopa and reduced falls in a trial of Parkinson patients with neurogenic orthostatic hypotension. Clin Neuropharmacol 2016;39:220-6.

Publication: Journal Article

Hauser, RA, S Heritier, GJ Rowse, LA Arthur Hewitt, and SH Isaacson. 2016. “Droxidopa and Reduced Falls in a Trial of Parkinson Patients With Neurogenic Orthostatic Hypotension. Clin Neuropharmacol 2016;39:220-6.”. Clin Neuropharmacol.

Correlates of excessive daytime sleepiness in de novo Parkinson's disease: A case control study. Mov Disord 2015;30:1371-81.

Publication: Journal Article

Simuni, T, Caspell Garcia, C Coffey, LM Chahine, S Lasch, WH Oertel, G Mayer, et al. 2015. “Correlates of Excessive Daytime Sleepiness in de Novo Parkinson’s Disease: A Case Control Study. Mov Disord 2015;30:1371-81.”. Mov Disord.

Long-term safety and efficacy of preladenant in subjects with fluctuating Parkinson's disease. Mov Disord 2013;28:817-20.

Publication: Journal Article

Factor, SA, K Wolski, DM Togasaki, S Huyck, M Cantillon, TW Ho, RA Hauser, and E Pourcher. 2013. “Long-Term Safety and Efficacy of Preladenant in Subjects With Fluctuating Parkinson’s Disease. Mov Disord 2013;28:817-20.”. Mov Disorders.

Randomized trial of cognitive speed of processing training in Parkinson disease. Neurology 2013;81:1284-90.

Publication: Journal Article

Edwards, JD, RA Hauser, ML O’Connor, EG Valdes, TA Zesiewicz, and EY Uc. 2013. “Randomized Trial of Cognitive Speed of Processing Training in Parkinson Disease. Neurology 2013;81:1284-90.”. Neurology.

The challenge of developing adenosine A2A antagonists for Parkinson disease: Istradefylline, preladenant, and tozadenant. Parkinsonism Relat Disord 2020;80 Suppl 1:S54-S63.

Publication: Journal Article

LeWitt, PA, SD Aradi, RA Hauser, and O Rascol. 2020. “The Challenge of Developing Adenosine A2A antagonists for Parkinson Disease: Istradefylline, Preladenant, and Tozadenant. Parkinsonism Relat Disord 2020;80 Suppl 1:S54-S63.”. Parkinsonism Relat Disord.

Striatal allografts in patients with Huntington's disease: impact of diminished astrocytes and vascularization on graft viability. Brain 2013;136(Pt 2):433-43.

Publication: Journal

Cisbani, G, TB Freeman, D Soulet, Saint Pierre, D Gagnon, M Parent, RA Hauser, RA Barker, and F Cicchetti. 2013. “Striatal Allografts in Patients With Huntington’s Disease: Impact of Diminished Astrocytes and Vascularization on Graft Viability. Brain 2013;136(Pt 2):433-43..”

Onset and duration of effect of extended-release carbidopa-levodopa in advanced Parkinson’s disease. Neuropsychiatr Dis Treat 2018;14:839-845.

Publication: Journal Article

Hauser, RA, A Ellenbogen, S Khanna, S Gupta, and NB Modi. 2018. “Onset and Duration of Effect of Extended-Release Carbidopa-Levodopa in Advanced Parkinson’s Disease. Neuropsychiatr Dis Treat 2018;14:839-845.”. Neuropsychiatr Dis Treat .